荣昌生物制药（烟台）股份有限公司 specializes in the development and commercialization of innovative drugs, specifically in the fields of autoimmune diseases and oncology, with products such as Telitacicept and Disitamab Vedotin.

荣昌生物制药（烟台）股份有限公司

RemeGen Biosciences | 6,932 followers on LinkedIn. Science with a purpose: creating innovative medicines to serve patients suffering from serious illnesses  | RemeGen Biosciences is a biopharmaceutical company, focusing on the discovery and development of innovative medicines for the treatment of cancer and autoimmune diseases, based in South San Francisco, California, and Rockville, Maryland. By leveraging our deep insights into oncology and immunology, advanced protein engineering/design technologies, and extensive knowledge in clinical development, our vision is to uncover the novel therapeutic targets and develop the best-in-class and first-in-class biotherapeutics for the patients with significant unmet medical needs. RemeGen Bioscience is a wholly owned subsidiary of RemeGen Co., a global pharmaceutic company specialized in autoimmune, oncology and ophthalmic diseases.

Executive Director, RemeGen Biosciences

Xiaoshan Min

VP of Biometrics at RemeGen Co., Ltd.

Chris X. Guo

Senior scientist at RemeGen Biosciences

Jing Zhou

Financial Executive

Li C.

RemeGen Biosciences

CrUX Dataset

CrUX Top 10m

Wang Weidong

Jianmin Fang

Co-Founder, CEO and CSO

Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.

Therapeutics Public Companies With More Than $1M in Revenue

China Companies With More Than 100 Employees (Top 10K)

Health Care Companies With Less Than $1B in Revenue (Top 10K)

Asia-Pacific (APAC) Public Companies With More Than 500 Employees (Top 10K)

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Lake Bleu Capital

Lilly Asia Ventures

Private Equity Round - Remegen

Yantai

Liaoning

China

Asia

Remegen

In the clinic for November 5, 2024

Regulatory actions for November 5, 2024

Regulatory actions for Oct. 30, 2024

Cash-Strapped Chinese Drugmaker RemeGen Denies Mass Layoffs

RemeGen Says ADC Successfully Targets Mesothelin in Solid Tumors

RemeGen Says anti-HER2 ADC Effective for Cervical Cancer

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients

RemeGen Hopes For Pain Relief From Expanded Drug Uses

RemeGen Publishes Data Showing Telitacicept Effective for Sjögren's Syndrome

RemeGen’s RC118 granted two orphan drug designations by FDA

United States

North America

United Kingdom

Europe

India

Spain

Croatia

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

RemeGen Co., Ltd.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 3:25 PM	21d59d1d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 3:25 PM	0531f798
crunchbase trigger	general	Nov 17, 2024 3:25 PM	fcb1db87
crunchbase profile	general	Nov 17, 2024 3:43 PM	95c1a75b
li profile	general	Nov 17, 2024 3:25 PM	741eec21
translate crunchbase fundingrounds	general	Nov 17, 2024 4:18 PM	d09c559e
peers	general	Nov 17, 2024 3:25 PM	41ebe080
news basic	general	Nov 17, 2024 3:25 PM	ebdb0ebe
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

9995

COM:REMEGEN

荣昌生物制药（烟台）股份有限公司

Last Close

18.06

22/11 08:08

Market Cap

14.40B

Beta: -

Volume Today

2.35M

Avg: -